Antibiotic-Resistant Organisms (AROs)
Quick Index
IPAC Canada is the first professional association to partner with the Canadian Antimicrobial Innovation Coalition (https://amrinnovation.ca/). This is an external consultative body comprised of members from Canada’s biomedical innovation sector to work jointly and openly with federal and provincial government representatives and identify opportunities to accelerate the development, commercialization and health care system adoption of biomedical innovation for AMR in Canada.
Related Links:
- Canadian Declaration on AntiMicrobial Resistance
- Biomedical Innovation in Antimicrobial Resistance (AMR): Fostering a Canadian Approach (background)
ARO Links
IPAC Canada offers these links for infection prevention and control professionals and others in health care.
Links presented here do not imply endorsement by IPAC Canada.
General ARO Resources
- Strengthening Governance of the Antimicrobial Resistance Response Across One Health in Canada.
- Antibiotic/Antimicrobial Resistance (CDC)
- Antimicrobial Resistance (NIAID)
- Antimicrobial Resistance (Pan American Health Organization)
- Antimicrobial Resistance in Long-Term Care Facilities (position paper from SHEA)
- Antimicrobial Use in Long-Term Care Facilities (position paper from SHEA)
- Canadian Agency for Drugs & Technologies in Health (CADTH) (summaries of reviews related to Infectious Diseases)
- Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)
- Antimicrobial Resistance - A Shared Responsibility (PHAC)
- Antibiotic Resistant Organism (ARO) Risk Factor-Based Screening Guidance for All Health Care Settings (PHO)
- European Antimicrobial Resistance Surveillance System (EARSS)
- National Antimicrobial Resistance Monitoring System (NARMS)(FDA)
- Northern Antibiotic Resistance Partnership (NARP)
- One Health Initiative (OHI) (Uniting human and veterinary medicine)
- Resistance Maps (Centre for Disease Dynamics, Economics and Policy)
- WHO Global Strategy for Containment of Antimicrobial Resistance
- Antimicrobial Resistance Information Bank (WHO)
- WHO Antimicrobial Resistance
- Canadian Antimicrobial Resistance Surveillance System (CARSS) Report 2022
- Antimicrobial Resistance in Canada: Findings from the 2022 Canadian Antimicrobial Resistance Surveillance System Report
- Antimicrobial use (AMU) in the Canadian community sector
- How Bacteria Build Resistance -George Washington University
Antibiotic Awareness and Antimicrobial Stewardship
- AMR Aware Canada
.png)
- AMR Aware Canada Resource Page & AMR Campaign Kit
- House of Commons Standing Committee on Health Study on Antimicrobial Resistance in Canada
- World AMR Awareness Week Resources (Patients for Patient Safety Canada)
- World AMR Awareness Week (WHO)
- Do Bugs Need Drugs?/ All languages
- President's Message [CJIC 2014, Vol. 29 No. 2]
- Position Statement: Antimicrobial Resistance Related to Animal Husbandry and Veterinary Medicine (2018)
- Antibiotic resistance awareness materials (PHAC)
- Antimicrobial Awareness Week (AMMI Canada)
- Antimicrobial Stewardship Program (PHO)
- Core Elements of an Antibiotic Stewardship Program (CDC)
- Antimicrobial Resistance Solutions Initiative (CDC)
- Be Antibiotics Aware Stakeholder Toolkit (CDC)
- AntibioticWise video
- Antibiotic Stewardship (IDSA)
- Alliance for the Prudent Use of Antibiotics (APUA)
- World AMR Awareness Week
- U.S. Antibiotic Awareness Week
- European Antibiotic Awareness Day
- Antibiotic Guardian
MRSA Resources
- Annex A: Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs) In All Health Care Settings (PIDAC 2013)
- Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) (PHAC)
- MRSA Guidelines (BC CDC)
- Guidelines for the Management of Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA)-related Skin and Soft tissue Infections in Primary Care (BC CDC)
- Methicillin Resistant Staphylococcus aureus (MRSA) (PHO)
- Legislative Mandates for Use of Active Surveillance Cultures to Screen for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci (position paper from SHEA/APIC)
- Methicillin-resistant Staphylococcus aureus (MRSA) (CDC)
- Methicillin-Resistant Staphylococcus aureus (MRSA) Screening and Discontinuation of Precautions in Hospitals: Clinical Effectiveness and Guidelines (CADTH)
- Polymerase Chain Reaction Tests for Methicillin-Resistant Staphylococcus aureus in Hospitalized Patients: Clinical and Cost-Effectiveness Analyses (CADTH)
VRE Resources
- Annex A: Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs) In All Health Care Settings (PIDAC 2013)
- Review of Literature for Evidence-based Best Practices for VRE Control (PIDAC)
- Legislative Mandates for Use of Active Surveillance Cultures to Screen for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci (position paper from SHEA/APIC)
- Management of Multidrug-Resistant Organisms In Healthcare Settings, (CDC)
- SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-resistant Strains of Staphylococcus aureus and Enterococcus
- Vancomycin-resistant Enterococci (VRE) (CDC)
- Vancomycin resistant Enterococci : prevention and control measures for long term care facilities - Quebec INSPQ
ESBL and CPE Resources
- Recommended practices for the prevention of endoscopy-related infections (PHAC 2016)
Pratiques recommandées pour la prévention d'infections liées à des endoscopies (ASPC 2016) - Annex A: Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs) In All Health Care Settings (PIDAC)
- Best Practices in IPAC Related to Gram-Negative Resistance (Toolkit from CHICA/APIC/ICNA)
- Carbapenem-Producing Enterobacteriaceae (CPE) Resources
- Interim Measures to Prevent and Control Transmission of Carbapenemase-producing Enterobacteriaceae and other Multidrug-Resistant Gram-Negative Bacilli in Long-term Care Settings (INSPQ 2018) French
- Annex A: Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs) In All Health Care Settings (PIDAC 2013)
- CPE Transmission Risk Factors in Long Term Care Homes (PHO)
- Resident Admission, Discharge, and Transfer Considerations for Carbapenemase-Producing Enterobacteriaceae (PHO)
- Infection Prevention and Control Measures for Healthcare Workers in All Healthcare Settings - Carbapenem-resistant Gram-negative Bacilli (PHAC 2010)
- Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase- Producing Enterobacteriaceae in Acute Care Facilities (CDC 2009)
- Public Health update of Carbapenem-Resistant Enterobacteriaceae (CRE) producing metallo-beta-lactamases (NDM, VIM, IMP) in the U.S. reported to CDC\CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) (CDC 2012
- Detection, Treatment and Prevention of Carbapenemase-Producing Enterobacteriaceae: Recommendations from an International Working Group (J Chemotherapy 2013)
NDM-1 Resources
- Lancet Infectious Diseases:
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study (Kumarasamy, 2010)
- The latest threat in the war on antimicrobial resistance (Pitout, 2010)
- Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern (Pitout, 2008)
- JAPI: "New Delhi Metallo-b lactamase (NDM-1) in Enterobacteriaceae: Treatment options with Carbapenems Compromised"
- U.S.: "Detection of Enterobacteriaceae Isolates Carrying Metallo-Beta-Lactamase -- United States, 2010"
C.difficile Resources
- C.difficile Fact Sheet (PHAC)
- Annex C: Testing, Surveillance and Management of Clostridium difficile in All Health Care Settings (PIDAC 2013)
- Clostridium difficile Infection - Infection Prevention and Control Guidance for Management in Long-term Care Facilities (PHAC 2013)
- Clostridium difficile Infection - Infection Prevention and Control Guidance for Management in Acute Care Settings (PHAC 2013)
- Guide to Preventing Clostridium difficile Infections (APIC 2013)
- Clostridium difficile in paediatric populations (CPS 2018)
Candida auris Resources
- Interim Guide for Infection Prevention and Control of Candida auris (PIDAC)
- Candida auris Infection Prevention and Control in Canadian Healthcare Settings (PHAC)
- Management of a Single New Case of Candida auris (PHO)
- Candida auris (CDC)
- WHO fungal priority pathogens list to guide research, development and public health action
- What health care providers need to know about Candida auris (CCDR-PHAC)
- Effectiveness of disinfectants against Candida auris and other Candida species (Abstract)
- First reported case of multidrug-resistant Candida auris in Canada (CCDR-PHAC)
- Candida auris Outbreak in a COVID-19 Specialty Care Unit — Florida, July–August 2020
- Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021
